Identification of epigenetic aberrant promoter methylation in serum DNA is useful for early detection of lung cancer

Clinical Cancer Research

Volumn 11, Issue 3, 2005, Pages 1219-1225

  Fujiwara, Keiichi ^a   Fujimoto, Nobukazu ^a   Tabata, Masahiro ^a   Nishii, Kenji ^b   Matsuo, Keitaro ^d   Hotta, Katsuyuki ^a   Kozuki, Toshiyuki ^a   Aoe, Motoi ^c   Kiura, Katsuyuki ^a   Ueoka, Hiroshi ^a   Tanimoto, Mitsune ^a  

^a OKAYAMA UNIVERSITY MEDICAL SCHOOL   (Japan)

^b Okayama Southern Institute of Health   (Japan)

^c OKAYAMA UNIVERSITY   (Japan)

^d AICHI CANCER CENTER HOSPITAL   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CARCINOEMBRYONIC ANTIGEN; CYTOKERATIN 19 FRAGMENT; DNA; PROGASTRIN RELEASING PEPTIDE; TUMOR MARKER;

ARTICLE; CANCER DIAGNOSIS; CANCER EPIDEMIOLOGY; CANCER SCREENING; CLINICAL FEATURE; DNA EXTRACTION; EPIGENETICS; FEMALE; FIBEROPTIC BRONCHOSCOPY; HUMAN; LUNG CANCER; MAJOR CLINICAL STUDY; MALE; METHYLATION; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; SERUM; STATISTICAL ANALYSIS; THORAX RADIOGRAPHY; TUMOR SUPPRESSOR GENE;

ADULT; AGED; AGED, 80 AND OVER; APOPTOSIS REGULATORY PROTEINS; CA(2+)-CALMODULIN DEPENDENT PROTEIN KINASE; CYCLIN-DEPENDENT KINASE INHIBITOR P16; DNA METHYLATION; DNA, NEOPLASM; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; O(6)-METHYLGUANINE-DNA METHYLTRANSFERASE; ODDS RATIO; PROMOTER REGIONS (GENETICS); RECEPTORS, RETINOIC ACID; RISK FACTORS; TIME FACTORS; TUMOR SUPPRESSOR PROTEINS;

EID: 19944433956     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (49)

1. Mountain CF. Revisions in the international system for staging lung cancer. Chest 1997;111:1710-7.
2. Ihde DC. Chemotherapy of lung cancer. N Engl J Med 1992;327:1434-41.
3. Nishii K, Ueoka H, Kiura K, et al. A case-control study of lung cancer screening in Okayama Prefecture, Japan. Lung Cancer 2001;34:325-32.
4. Melamed MR, Flehinger BJ, Zaman MB, Heelan RT, Parchick WA, Martini N. Screening for early lung cancer: results of the Memorial Sloan-Kettering study in New York. Chest 1984;86:44-53.
5. Fontana RS, Sanderson DR, Woolner LB, Taylor WF, Miller WE, Muhm JR. Lung cancer screening: the Mayo program. J Occup Med 1986;28:746-50.
6. Tockman MS. Survival and mortality from lung cancer in a screened population: the Johns Hopkins Study. Chest 1986;89:324-5S.
7. Marcus PM, Bergstralh EJ, Fagerstrom RM, et al. Lung cancer mortality in the Mayo Lung Project: impact of extended follow up. J Natl Cancer Inst 2000;92:1308-16.
8. Smith RA, Cokkinides V, Eyre HJ; American Cancer Society. American Cancer Society guidelines for the early detection of cancer, 2003. CA Cancer J Clin 2003;53:27-43.
9. Baylin SB, Herman JG, Graff JR, Vertino PM, Issa JP. Alterations in DNA methylation: a fundamental aspect of neoplasia. Adv Cancer Res 1998;72:141-96.
10. Baylin SB, Esteller M, Rountree MR, Bachman KE, Schuebel K, Herman JG. Aberrant patterns of DNA methylation, chromatin formation and gene expression in cancer. Hum Mol Genet 2001;10:687-92.
11. Merlo A, Herman JG, Mao L, et al. 5′ CpG island methylation is associated with transcriptional silencing of the tumor suppressor p16/CDKN2/MTS1 in human cancers. Nat Med 1995;1:686-92.
12. INK4a is an early event in lung cancer and a potential biomarker for early diagnosis. Proc Natl Acad Sci U S A 1998;95:11891-6.
13. Herman JG, Graff JR, Myohanen S, Nelkin BD, Baylin SB. Methylation-specific PCR: a novel PCR assay for methylation status of CpG islands. Proc Natl Acad Sci U S A 1996;93:9821-6.
14. Virmani AK, Rathi A, Zochbauer-Muller S, et al. Promoter methylation and silencing of the retinoic acid receptor-β gene in lung carcinomas. J Natl Cancer Inst 2000;92:1303-7.
15. Kashiwabara K, Oyama T, Sano T, Fukuda T, Nakajima T. Correlation between methylation status of the p16/CDKN2 gene and the expression of p16 and Rb proteins in primary non-small cell lung cancers. Int J Cancer 1998;79:215-20.
16. INK4a promoter hypermethylation, p53 mutation, and K-ras mutation in exfoliative material mark the development of lung cancer in symptomatic chronic smokers. J Clin Oncol 2000;18:3221-9.
17. Tang X, Khuri FR, Lee JJ, et al. Hypermetylation of the death-associated protein (DAP) kinase promoter and aggressiveness in stage I non-small-cell lung cancer. J Natl Cancer Inst 2000;92:1511-6.
18. Burbee DG, Forgacs E, Zochbauer-Muller S, et al. Epigenetic inactivation of RASSF1A in lung and breast cancers and malignant phenotype suppression. J Natl Cancer Inst 2001;93:691-9.
19. Dammann R, Takahashi T, Pfeifer GP. The CpG island of the novel tumor suppressor gene RASSF1A is intensely methylated in primary small cell lung carcinomas. Oncogene 2001;20:3563-7.
20. Zochbauer-Muller S, Fong KM, Virmani AK, Geradts J, Gazdar AF, Minna JD. Aberrant promoter methylation of multiple genes in non-small cell lung cancers. Cancer Res 2001;61:249-55.
21. Esteller M, Cor PG, Baylin SB, Herman JG. A gene hypermethylation profile of human cancer. Cancer Res 2001;61:3225-9.
22. Leon SA, Shapiro B, Sklaroff DM, Yaros MJ. Free DNA in the serum of cancer patients and the effect of therapy. Cancer Res 1977;37:646-50.
23. Stroun M, Anker P, Maurice P, Lyautey J, Lederrey C, Beljanski M. Neoplastic characteristics of the DNA found in the plasma of cancer patients. Oncology 1989;46:318-22.
24. Shapiro B, Chakrabaty M, Cohn E, Leon SA. Determination of circulating DNA levels in patients with benign or malignant gastrointestinal diseases. Cancer (Phila) 1983;51:2116-20.
25. Nawroz H, Koch W, Anker P, Stroun M, Sidransky D. Microsatellite alterations in serum DNA of head and neck cancer patients. Nat Med 1996;2:1035-7.
26. Chen XQ, Stroun M, Magnenat JL, et al. Microsatellite alterations in plasma DNA of small cell lung cancer patients. Nat Med 1996;2:1033-7.
27. Hibi K, Robinson R, Wu L, Hamilton SR, Sidransky D, Jen J. Molecular detection of genetic alterations in the serum of colorectal cancer patients. Cancer Res 1998;58:1405-7.
28. Mulcahy HE, Lyautey J, Lederrey C, et al. A prospective study of K-ras mutations in the plasma of pancreatic cancer patients. Clin Cancer Res 1998;4:271-5.
29. Miyamoto H. Establishment and characterization of an Adriamycin-resistant subline of human small cell lung cancer cells. Acta Med Okayama 1986;40:65-73.
30. WHO. Histological typing of lung and pleural tumors. 3rd ed. Geneva: WHO; 1999.
31. Zochbauer-Muller S, Minna JD, Gazdar AF. Aberrant DNA methylation in lung cancer: biological and clinical implications. Oncologist 2001;7:451-7.
32. Usadel H, Brabender J, Danenberg KD, et al. Quantitative adenomatous polyposis coli promoter methylation analysis in tumor tissue, serum, and plasma DNA of patients with lung cancer. Cancer Res 2002;62:371-5.
33. Laird PW. The power and the promise of DNA methylation markers. Nat Rev Cancer 2003;3:253-66.
34. Esteller M, Sanchez-Cespedes M, Rosell R, Sidransky D, Baylin SB, Herman JG. Detection of aberrant promoter hypermethylation of tumor suppressor genes in serum DNA from non-small cell lung cancer patients. Cancer Res 1999;59:67-70.
35. Katzenellenbogen RA, Baylin SB, Herman JG. Hypermethylation of the DAP-kinase CpG island is a common alteration in B-cell malignancies. Blood 1999;93:4347-53.
36. An Q, Liu Y, Gao Y, et al. Detection of p16 hypermethylation in circulating plasma DNA of non-small cell lung cancer patients. Cancer Lett 2002;188:109-14.
37. 6-methylguanine DNA methyltransferase methylation analysis in curatively resected non-small cell lung cancer: associations with clinical outcome. Clin Cancer Res 2003;9:223-7.
38. Harden SV, Tokumaru Y, Westra WH, et al. Gene promoter hypermethylation in tumors and lymph nodes of stage I lung cancer patients. Clin Cancer Res 2003;9:1370-5.
39. Eads CA, Danenberg KD, Kawakami K, et al. MethyLight: a high-throughput assay to measure DNA methylation. Nucleic Acids Res 2000;28:E32.
40. Tsou JA, Hagen JA, Carpenter CL, Laird-Offringa IA. DNA methylation analysis: a powerful new tool for lung cancer diagnosis. Oncogene 2002;12:5450-61.
41. Belinsky SA, Palmisano WA, Gilliland FD, et al. Aberrant promoter methylation in bronchial epithelium and sputum from current and former smokers. Cancer Res 2002;62:2370-7.
42. Palmisano WA, Divine KK, Saccomanno G, et al. Predicting lung cancer by detecting aberrant promoter methylation in sputum. Cancer Res 2000;60:5954-8.
43. Soria JC, Rodriguez M, Liu DD, Lee JJ, Hong W K, Mao L. Aberrant promoter methylation of multiple genes in bronchial brush samples from former cigarette smokers. Cancer Res 2002;62:351-5.
44. Kim DH, Nelson HH, Wiencke JK, et al. p16(INK4a) and histology-specific methylation of CpG islands by exposure to tobacco smoke in non-small cell lung cancer. Cancer Res 2001;61:3419-24.
45. Henschke CI, McCauley DI, Yankelevitz DF, et al. Early lung cancer action project: overall design and findings from baseline screening. Lancet 1999;354:99-105.
46. Swensen SJ, Jet JR, Sloan JA, et al. Screening for lung cancer with low-dose spiral computed tomography. Am J Respir Crit Care Med 2002;165:508-13.
47. McWilliams A, MacAulay C, Gazdar AF, et al. Innovative molecular and imaging approaches for the detection of lung cancer and its precursor lesions. Oncogene 2002;21:6949-59.
48. Sone S, Takashima S, Li F, et al. Mass screening for lung cancer with mobile spiral computed tomography scanner. Lancet 1998;351:1242-5.
49. Mulshine JL. Screening for lung cancer: in pursuit of pre-metastatic disease. Nat Rev Cancer 2003;3:65-73.